Inveready and the CDTI through the INNVIERTE program will invest €2.3 million of capital. This amount will be complemented by €2.7 million through other instruments and public funds that have already been obtained. With these funds, aptaTargets plans to advance up to a clinical proof of concept in acute ischemic stroke patients.
Ramirez-Carracedo et al. Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction.
The ApTOLL project aims to advance in the preclinical development of a molecule based on aptamer technology for acute stroke and myocardial infarction. The consortium is led by the company aptaTargets and are also participating Aptus Biotech, the Neurovascular Research Unit (Complutense University) and the Institute of Biomedical Research (UAM-CSIC). The project is funded by the Ministry of Economy and Competitiveness and funds from the European Union, within the objective of promoting the technological development, innovation and research.
aptaTargets participated in the round table about therapeutic aptamers, presenting the nonclinical program.
aptaTargets participated in the round table about therapeutic aptamers, presenting the nonclinical program, regulatory management and preliminary results in First-in-Human trial.
aptaTargets presented the ApTOLL clinical program and nonclinical studies in experimental stroke models.
(European Stroke Organization Conference)
aptaTargets presented the First-in-Human clinical study design.